Charles River Laboratories
$ 166.06
1.55%
24 Feb - close price
- Market Cap 8,172,721,000 USD
- Current Price $ 166.06
- High / Low $ 168.98 / 161.43
- Stock P/E N/A
- Book Value 64.30
- EPS -1.53
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE -0.04 %
- 52 Week High 228.88
- 52 Week Low 91.86
About
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Analyst Target Price
$196.87
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-19 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-14 | 2023-11-08 | 2023-08-09 | 2023-05-11 |
| Reported EPS | 2.39 | 2.43 | 3.12 | 2.34 | 2.66 | 2.59 | 2.8 | 2.27 | 2.46 | 2.72 | 2.69 | 2.78 |
| Estimated EPS | 2.35 | 2.35 | 2.55 | 2.07 | 2.53 | 2.42 | 2.39 | 2.07 | 2.4 | 2.37 | 2.64 | 2.59 |
| Surprise | 0.04 | 0.08 | 0.57 | 0.27 | 0.13 | 0.17 | 0.41 | 0.2 | 0.06 | 0.35 | 0.05 | 0.19 |
| Surprise Percentage | 1.7021% | 3.4043% | 22.3529% | 13.0435% | 5.1383% | 7.0248% | 17.1548% | 9.6618% | 2.5% | 14.7679% | 1.8939% | 7.3359% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.55 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRL
2026-02-24 19:49:57
Baird has maintained its Outperform rating on Charles River Laboratories International, Inc. (CRL) despite a reduced price target from $231 to $193, based on revised models following the company's fourth-quarter results. Mizuho Securities also lowered its price target and maintained a Neutral rating due to expectations of slower organic growth and lower free cash flow, along with broader AI-related concerns. Charles River Laboratories, a pre-clinical contract research organization, is considered one of the top 10 life sciences stocks by hedge funds, although the article suggests other AI stocks might offer greater upside and less risk.
2026-02-24 05:50:06
Charles River Laboratories International (CRL) saw its stock decline despite an earnings beat and positive 2026 guidance, suggesting a market reset. Simply Wall St's analysis indicates CRL is undervalued by 24.2%, with a fair value of $215.73 against a last close of $163.52, driven by revenue growth assumptions and margin improvement. However, this valuation is contingent on sustained CRO demand and biotech funding, with potential risks from cancellations or pricing pressure.
2026-02-24 05:25:09
Charles River Laboratories International (CRL) saw its stock draw attention after exceeding Q4 earnings and revenue forecasts and providing optimistic 2026 guidance. Despite recent share price declines, the company is considered undervalued by analysts and models, with a fair value of $215.73 against a last close of $163.52. This valuation is underpinned by strategic investments in diversification, automation, and digitalization, positioning CRL for future margin stability and growth in complex testing markets.
2026-02-23 17:20:45
Shares of Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories plummeted after the Trump administration announced new global tariffs. This decision, invoking the Trade Act of 1974 to impose a 15% global tariff, created significant uncertainty for companies reliant on international supply chains. Investors are now assessing the potential impact on corporate earnings and broader economic activity.
2026-02-23 17:01:06
Shares of Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories plummeted after the administration announced new global tariffs using the Trade Act of 1974. This move came despite a recent Supreme Court ruling against using a different act for such duties, creating significant uncertainty for companies with international supply chains. Investors are now assessing the potential impact on corporate earnings and economic activity, with Charles River Laboratories specifically noted for its stock volatility and recent strong quarterly results despite the current dip.
2026-02-23 01:23:37
Charles River Laboratories recently reported Q4 and full-year 2025 results, including a net loss due to significant impairment charges and new 2026 guidance for flat to 1.5% revenue growth and GAAP EPS of US$6.30 to US$6.80. The company also announced leadership changes, signaling a focus on financial discipline and governance. This report examines how these developments, including new guidance and leadership, will shape investor expectations for Charles River's future performance and financial health.
